{
    "organizations": [],
    "uuid": "95703e7b8412551ac9336872d832889cf1e6d148",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-allergan-and-richter-say-bipolar-i/brief-allergan-and-richter-say-bipolar-i-depression-study-meets-main-goal-idUSFWN1RG0JY",
    "ord_in_thread": 0,
    "title": "BRIEF-Allergan And Richter Say Bipolar I Depression Study Meets Main Goal",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Allergan Plc - For Rgh-Md :\n* ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM THIRD OF THREE PIVOTAL TRIALS OF CARIPRAZINE IN BIPOLAR I DEPRESSION\n* PRIMARY ENDPOINT WAS MET IN STUDY EVALUATING PATIENTS WITH ACUTE BIPOLAR I DEPRESSION TREATED WITH CARIPRAZINE 1.5 MG VERSUS PLACEBO\n* CARIPRAZINE WAS GENERALLY WELL TOLERATED IN TRIAL * PLANS TO INCLUDE DATA FROM ALL THREE PIVOTAL TRIALS IN COâ€™S SNDA TO U.S. FDA IN SECOND HALF OF 2018\n* MOST COMMONLY REPORTED ADVERSE EVENTS IN CARIPRAZINE GROUPS WERE AKATHISIA, RESTLESSNESS, NAUSEA, AND FATIGUE\n* EFFICACY OF CARIPRAZINE IN TREATMENT OF BIPOLAR I DEPRESSION HAS BEEN DEMONSTRATED IN THREE POSITIVE PIVOTAL TRIALS\n* 53, PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS WERE MET FOR CARIPRAZINE 1.5 MG DOSE GROUP Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T20:21:00.000+03:00",
    "crawled": "2018-04-04T12:23:19.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "allergan",
        "plc",
        "allergan",
        "richter",
        "announce",
        "positive",
        "topline",
        "result",
        "third",
        "three",
        "pivotal",
        "trial",
        "cariprazine",
        "bipolar",
        "depression",
        "primary",
        "endpoint",
        "met",
        "study",
        "evaluating",
        "patient",
        "acute",
        "bipolar",
        "depression",
        "treated",
        "cariprazine",
        "mg",
        "versus",
        "placebo",
        "cariprazine",
        "generally",
        "well",
        "tolerated",
        "trial",
        "plan",
        "include",
        "data",
        "three",
        "pivotal",
        "trial",
        "co",
        "snda",
        "fda",
        "second",
        "half",
        "commonly",
        "reported",
        "adverse",
        "event",
        "cariprazine",
        "group",
        "akathisia",
        "restlessness",
        "nausea",
        "fatigue",
        "efficacy",
        "cariprazine",
        "treatment",
        "bipolar",
        "depression",
        "demonstrated",
        "three",
        "positive",
        "pivotal",
        "trial",
        "primary",
        "key",
        "secondary",
        "efficacy",
        "endpoint",
        "met",
        "cariprazine",
        "mg",
        "dose",
        "group",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}